Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 232

1.

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.

Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL.

Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873-6. doi: 10.1016/j.ygyno.2019.12.043. [Epub ahead of print]

PMID:
31924332
2.

Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Monk BJ, Mayadev J, Nunes AT.

Gynecol Oncol Rep. 2019 Oct 10;30:100506. doi: 10.1016/j.gore.2019.100506. eCollection 2019 Nov.

3.

Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy.

Perkins V, Moore K, Vesely S, Matsuo K, Mostofizadeh S, Sims TT, Lea J, Barnes D, Chen S, Carlson M, Roman L, Monk BJ, Holman LL.

Gynecol Oncol. 2019 Dec 3. pii: S0090-8258(19)31620-8. doi: 10.1016/j.ygyno.2019.10.033. [Epub ahead of print]

PMID:
31810653
4.

Moving beyond cytotoxic drug dosing in ovarian cancer.

Eskander RN, Monk BJ.

Lancet. 2019 Dec 7;394(10214):2043-2045. doi: 10.1016/S0140-6736(19)32948-4. Epub 2019 Nov 29. No abstract available.

5.

Reply to Farolfi et al and Haines et al.

Tewari KS, Monk BJ, Burger RA.

J Clin Oncol. 2020 Jan 10;38(2):173-174. doi: 10.1200/JCO.19.02334. Epub 2019 Nov 7. No abstract available.

PMID:
31697589
6.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.

N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.

PMID:
31562799
7.

Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.

Grivas P, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, Hennessy D, Makris C, Moehler M.

Target Oncol. 2019 Oct;14(5):505-525. doi: 10.1007/s11523-019-00665-1. Review.

PMID:
31535338
8.

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.

Tewari KS, Monk BJ.

J Clin Oncol. 2019 Sep 20;37(27):2472-2489. doi: 10.1200/JCO.18.02303. Epub 2019 Aug 12. No abstract available. Erratum in: J Clin Oncol. 2019 Nov 1;37(31):2956.

PMID:
31403858
9.

The American Society of Clinical Oncology 2019 annual meeting: A review and summary of selected abstracts.

Duska LR, Gibson SJ, Beall SC, Monk BJ.

Gynecol Oncol. 2019 Sep;154(3):454-460. doi: 10.1016/j.ygyno.2019.06.019. Epub 2019 Jul 12. No abstract available.

PMID:
31303254
10.

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS.

Gynecol Oncol. 2019 Aug;154(2):420-425. doi: 10.1016/j.ygyno.2019.05.013. Epub 2019 Jun 19.

11.

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.

J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.

PMID:
31216226
12.

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.

Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR.

J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7.

PMID:
31173551
13.

The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer.

Monk BJ, Randall LM, Grisham RN.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e141-e151. doi: 10.1200/EDBK_239007. Epub 2019 May 17. Review.

14.

Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis.

Łaniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, Greenspan DL, Chase DM, Herbst-Kralovetz MM.

Sci Rep. 2019 May 14;9(1):7333. doi: 10.1038/s41598-019-43849-5.

15.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
16.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.

Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30948273
17.

Relationship between social support, quality of life, and Th2 cytokines in a biobehavioral cancer survivorship trial.

Osann K, Wilford J, Wenzel L, Hsieh S, Tucker JA, Wahi A, Monk BJ, Nelson EL.

Support Care Cancer. 2019 Sep;27(9):3301-3310. doi: 10.1007/s00520-018-4617-z. Epub 2019 Jan 5.

PMID:
30612237
18.

Response to "surgical management of cervical cancer by laparoscopy or laparotomy".

Leath CA 3rd, Monk BJ.

Gynecol Oncol Rep. 2018 Nov 20;27:6-7. doi: 10.1016/j.gore.2018.11.005. eCollection 2019 Feb. No abstract available.

19.

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian C.

Gynecol Oncol. 2018 Dec;151(3):422-427. doi: 10.1016/j.ygyno.2018.10.001. Epub 2018 Oct 8.

20.

The American Society of Clinical Oncology 2018 annual meeting: A review and summary of selected abstracts.

Rimel BJ, Gibson SJ, Beall SC, Monk BJ.

Gynecol Oncol. 2018 Nov;151(2):e1-e6. doi: 10.1016/j.ygyno.2018.08.018. Epub 2018 Aug 31. No abstract available.

PMID:
30174175

Supplemental Content

Loading ...
Support Center